TNFRSF8 and classic Hodgkin lymphoma: Moreover, the use of BV has also been expanded to other lymphomas, such as other peripheral T‐cell lymphomas and B‐cell non‐Hodgkin lymphomas, and our results suggest that BV might be a promising option for CD30‐positive lymphomas apart from cHL and ALCL, with the ORR reaching 56.8%, the 6‐month PFS rate reaching 69.9% and the 6‐month OS rate reaching 83.1%, supporting the conclusions from clinical trials.12